GLOBAL TRIALS : New Survey Baselines Global Sites Keys to Success in China Budgeting for Global Trials European Ethics Committees CRO/SPONSOR : Think About the Drug Label First LABS : 3-Prong Model for CV Safety Immune Response Screens a Necessity eCLINICAL : ePRO?s Tipping Point Also in this issue : FDA?s New Risk Approach to Site Inspections, EMA Speaks to Stem Cell Research, Mother Lode of Latent Research Data
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.